Abiraterone NEW

Abiraterone is a cytochrome CYP17(17α-hydroxylase /C17, 20-lyase) inhibitor that is hydrolyzed to produce abiraterone. Abiraterone acetate reduces testosterone production by inhibiting cytochrome CYP17 and is indicated for patients with metastatic castration-resistant prostate cancer (CRPC) who have received previous chemotherapy containing paclitaxel. Clinical trials demonstrated that abiraterone combined with prednisone significantly extended overall survival in patients with metastatic prostate cancer who had previously received docetaxel chemotherapy. Subsequent studies found that abiraterone was equally effective in patients who did not receive docetaxel chemotherapy, and abiraterone was recommended as first-line therapy for metastatic CRPC. Recent studies have shown that abiraterone can benefit patients with locally advanced or metastatic prostate cancer. These results will promote the early entry of abiraterone into the first line of treatment for advanced prostate cancer.

Currently, castration treatments, including drugs and surgery, are generally preferred by patients with advanced prostate cancer to reduce testosterone synthesis in the testes, but this treatment does not inhibit the production of androgens elsewhere in the body. Abiraterone, a prostate cancer treatment known as Abiraterone that is not yet available in the country, was created by researchers at the Royal Marsden Hospital in southwest London, a world-renowned cancer research treatment center. It can inhibit the production of androgens in any part of the body, and can not only reduce the level of prostate-specific antigen (PSA), which represents tumor activity, but also help shrink tumors. It is also suitable for tumor patients who have had chemotherapy in the past, showing promising treatment. Abiraterone was previously owned by Cougar Biopharmaceutical, a British company, but Johnson & Johnson acquired Cougar Biologics for $970 million in 2009 to license the drug. This product can significantly prolong the life of patients with advanced prostate cancer, including those who have taken one or two chemotherapeutics containing polyene purpurinol, but their disease has worsened, and the side effects of the drug are minimal and the safety is good. Abiraterone is an oral cytochrome oxidase P450(CYP450)c17 inhibitor that reduces androgen levels by inhibiting CYP450c17, a key enzyme in androgen synthesis, and inhibits androgens in the testes and other parts of the body.